7
total announcements
524731.BO · 15 min delayed
Jenburkt Pharmaceuticals Ltd
Jenburkt Pharmaceuticals Ltd has published its standalone unaudited financial results for the quarter ended on 30th June, 2026. The results are available on the company's website and the BSE website.
Jenburkt Pharmaceuticals Ltd
Jenburkt Pharmaceuticals Ltd has announced its standalone unaudited financial results for the quarter ended on 30th June, 2026, with a profit before tax of Rs. 676.91 crores and a net profit of Rs. 588.56 crores.
Jenburkt Pharmaceuticals Ltd
Jenburkt Pharmaceuticals Ltd has announced its standalone unaudited financial results for the quarter ended 30 June 2026, with revenue from operations at Rs 3551.20 crore and profit after tax at Rs 588.56 crore.
Jenburkt Pharmaceuticals Ltd
Jenburkt Pharmaceuticals Ltd has announced the notice of its 41st Annual General Meeting (AGM) to be held on September 4, 2026, through video conferencing. The notice, along with the annual report for the financial year 2025-26, has been sent to members through electronic mode. Members will be able to cast their votes using the electronic voting system provided by National Securities Depository Limited (NSDL) from September 1 to 3, 2026.
Jenburkt Pharmaceuticals Ltd
Jenburkt Pharmaceuticals Ltd has announced the notice of its 41st Annual General Meeting (AGM) to be held on September 4, 2026, through video conferencing. The meeting will consider various resolutions, including the adoption of audited financial statements, dividend declaration, and reappointment of the Whole Time Director and CFO.
Jenburkt Pharmaceuticals Ltd
Jenburkt Pharmaceuticals Ltd has submitted its Annual Report for FY 2025-26, including audited standalone financial statements, auditors' report, and directors' report. The report also includes a notice convening the 41st Annual General Meeting to be held on September 4, 2026, and proposes to declare a dividend of ₹ 20.70 per equity share.
Jenburkt Pharmaceuticals Ltd
Jenburkt Pharmaceuticals Ltd has scheduled a Board Meeting on 06/08/2026 to consider and approve standalone unaudited financial results for the quarter ended 30/06/2026.